All In Biotech

Drug Trial Radar · NCT07230288

Study of ABBV-142 to Assess Adverse Events and Change in Disease Activity in Adult Participants With Idiopathic Pulmonary Fibrosis

A Phase 2a Multicenter Platform Study of Investigational Products for the Treatment of Adult Subjects With Idiopathic Pulmonary Fibrosis

Last checked: Nov 19, 2026Latest source record: Sep 3, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

RecruitingPivotal-lookingRandomized with 165 participants. This is a heuristic, not a regulatory label.

Status

Recruiting

Enrollment

165

Planned (sponsor's estimate)

Start

Jan 23, 2026

Primary completion

Sep 2029

Study completion Sep 2029

Sponsor

Lead sponsor
AbbVieAbbVie (ABBV)
Sponsor type
Industry
First posted
Nov 17, 2025

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 2
Allocation
Randomized
Model
Parallel
Masking
Quadruple (participant, care provider, investigator, outcomes assessor)
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 40 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

Idiopathic Pulmonary Fibrosis (IPF) is a rare, long-lasting lung disease that causes scarring of lung tissue, shortness of breath, and loss of lung function. IPF leads to significant loss of quality of life and shortened lifespan. This study is a platform study evaluating different types of treatments in patients with IPF. A platform study is a type of study that uses a single master protocol to evaluate different study treatments allowing for new study treatments or substudies to be added or closed over time. The main goals of the study are to evaluate the safety, tolerability (the degree to which the adverse symptoms can be handled by the patients during the study) and efficacy (how well study treatment works) of the study treatments, including ABBV-142 in Substudy 1 (SS1). ABBV-142 is an investigational drug being developed for the treatment of IPF. In SS1, participants will be randomly assigned to one of the 2 groups to receive either ABBV-142 or a matching placebo. This study is "double-blind", meaning that neither the participants nor the study doctors know who is given which study treatment. Approximately 165 adult participants with IPF will be enrolled in approximately 125 sites across the world. Participants will receive ABBV-142 or matching placebo for 52 weeks during the double-blind treatment period. Eligible participants may receive ABBV-142 for 52 weeks in open-label treatment period. All participants will be followed for 120 days. There may be higher treatment burden for participants in this trial compared to their standard of care. Participants will attend regular visits during the study at a hospital or clinic. The effect of the treatment will be checked by medical assessments, blood tests, checking for side effects and completing questionnaires.

Conditions

  • Idiopathic Pulmonary Fibrosis

Interventions

  • ABBV-142Drug

    ABBV-142

  • Placebo for ABBV-142Drug

    Placebo for ABBV-142

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Absolute Change From Baseline in Forced Vital Capacity (FVC) (mL)Time frame: Week 24
  2. Percentage of Participants with Adverse Events (AE)Time frame: Up to approximately 52 weeks

Locations

57 sites in 17 countries. Site status is shown where the registry gives one.

  • The University of Alabama at Birmingham /ID# 277613

    Birmingham, Alabama · Recruiting

  • Sec Clinical Research - East - Dothan - Graceland /ID# 278328

    Dothan, Alabama · Recruiting

  • Clinical Research Specialists - Kissimmee /ID# 279184

    Kissimmee, Florida · Recruiting

  • Christie Clinic on University /ID# 277871

    Champaign, Illinois · Recruiting

  • University of Michigan Health System - Ann Arbor /ID# 279994

    Ann Arbor, Michigan · Recruiting

  • Henry Ford Hospital /ID# 277843

    Detroit, Michigan · Recruiting

  • Hannibal Regional Hospital /ID# 277984

    Hannibal, Missouri · Recruiting

  • Jefferson Health Honickman Center /ID# 279127

    Philadelphia, Pennsylvania · Recruiting

  • Inova Fairfax Hospital /ID# 278469

    Falls Church, Virginia · Recruiting

  • Virginia Commonwealth University Medical Center /ID# 277992

    Richmond, Virginia · Recruiting

  • Lung Research Queensland /ID# 278838

    Nundah, Queensland, Australia · Recruiting

  • Eastern Health /ID# 278245

    Box Hill, Victoria, Australia · Recruiting

  • University Multiprofile Hospital for Active Treatment Dr. Georgi Stranski /ID# 277845

    Pleven, Bulgaria · Recruiting

  • University Multiprofile Hospital For Active Treatment Sveti Georgi - Plovdiv /ID# 279367

    Plovdiv, Bulgaria · Recruiting

  • Acibadem City Clinic Tokuda University Hospital EAD /ID# 277846

    Sofia, Bulgaria · Recruiting

  • Diagnostic Consultative Center Convex /ID# 277848

    Sofia, Bulgaria · Recruiting

  • Diagnostic Consultative Center Convex /ID# 277849

    Sofia, Bulgaria · Recruiting

  • Centre d'Investigation Clinique Mauricie /ID# 277949

    Trois-Rivières, Quebec, Canada · Recruiting

  • Hopital Arnaud de Villeneuve /ID# 278322

    Montpellier, Herault, France · Recruiting

  • Hopital Avicenne /ID# 279212

    Bobigny, Île-de-France Region, France · Recruiting

  • Centre Hospitalier Universitaire de Rennes - Hopital Pontchaillou /ID# 278333

    Rennes, Ille-et-Vilaine, France · Recruiting

  • Klinikum Konstanz /ID# 278139

    Konstanz, Baden-Wurttemberg, Germany · Recruiting

  • Caritas-Krankenhaus St. Maria gGmbH /ID# 278138

    Donaustauf, Bavaria, Germany · Recruiting

  • University Hospital of Ioannina /ID# 277719

    Ioannina, Greece · Recruiting

  • General Hospital of Thessaloniki George Papanikolaou /ID# 277819

    Thessaloniki, Greece · Recruiting

  • University General Hospital of Patras /ID# 277726

    Pátrai, Achaia, Greece · Recruiting

  • General Hospital of Chest Diseases of Athens SOTIRIA /ID# 277724

    Athens, Attica, Greece · Recruiting

  • University General Hospital of Heraklion /ID# 277717

    Heraklion, Crete, Greece · Recruiting

  • NHO Kinki Chuo Chest Medical Center /ID# 280225

    Sakai-shi, Osaka, Japan · Recruiting

  • Vitamed Galaj i Cichomski Sp.j. /ID# 278145

    Bydgoszcz, Kuyavian-Pomeranian Voivodeship, Poland · Recruiting

  • Unidade Local de Saude do Algarve, EPE /ID# 278388

    Faro, Portugal · Recruiting

  • Unidade Local de Saude de Loures-Odivelas-Hospital Beatriz Angelo /ID# 278357

    Loures, Lisbon District, Portugal · Recruiting

  • Unidade Local de Saude de Matosinhos EPE /ID# 277980

    Senhora da Hora, Porto District, Portugal · Recruiting

  • University Clinical Center Serbia /ID# 278496

    Belgrade, Beograd, Serbia · Recruiting

  • Institute For Pulmonary Diseases Of Vojvodina /ID# 278499

    Kamenitz, Sremski Okrug, Serbia · Recruiting

  • Dr Hannes J van Rensburg inc /ID# 278278

    Cape Town, Western Cape, South Africa · Recruiting

  • Dr JM Engelbrecht Trial Site /ID# 278287

    Somerset West, Western Cape, South Africa · Recruiting

  • Inje University Haeundae Paik Hospital /ID# 278000

    Busan, Busan Gwang Yeogsi, South Korea · Recruiting

  • The Catholic University Of Korea, Bucheon St. Mary'S Hospital /ID# 278068

    Bucheon-si, Gyeonggido, South Korea · Recruiting

  • Seoul National University Bundang Hospital /ID# 278059

    Seongnam-si, Gyeonggido, South Korea · Recruiting

Showing 40 of 57 sites, US sites first. The full list is on the registry record.

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.